Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2021)

Historic Non Operating Investment Income for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Q1 2021 value amounting to $6.0 million.

  • Lineage Cell Therapeutics' Non Operating Investment Income rose 37885.53% to $6.0 million in Q1 2021 from the same period last year, while for Dec 2021 it was $6.0 million, marking a year-over-year increase of 3210.53%. This contributed to the annual value of $6.0 million for FY2021, which is 3210.53% up from last year.
  • According to the latest figures from Q1 2021, Lineage Cell Therapeutics' Non Operating Investment Income is $6.0 million, which was up 37885.53% from $712000.0 recorded in Q4 2020.
  • In the past 5 years, Lineage Cell Therapeutics' Non Operating Investment Income registered a high of $6.0 million during Q1 2021, and its lowest value of -$4.5 million during Q3 2019.
  • In the last 4 years, Lineage Cell Therapeutics' Non Operating Investment Income had a median value of $397000.0 in 2018 and averaged $680307.7.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Non Operating Investment Income was 79813.95% (2019), while the steepest drop was 1948260.87% (2019).
  • Over the past 4 years, Lineage Cell Therapeutics' Non Operating Investment Income (Quarter) stood at $523000.0 in 2018, then tumbled by 54.88% to $236000.0 in 2019, then surged by 201.69% to $712000.0 in 2020, then surged by 746.07% to $6.0 million in 2021.
  • Its last three reported values are $6.0 million in Q1 2021, $712000.0 for Q4 2020, and $120000.0 during Q3 2020.